AstraZeneca signs deal to promote product made in China — in mainland China; Israeli deep brain stimulation co Brainsway sets stage for $30M Nasdaq IPO
→ In what is being touted as the first time a multinational pharma company has secured a licence to sell a drug in China developed by a Chinese drugmaker, Luye Pharma on Wednesday said it had granted British drugmaker AstraZeneca $AZN the exclusive rights to promote its lipid-regulating Xuezhikang capsules, in mainland China. The manufacturer of the two decades old product, made by fermenting special red yeast rice, will retain all other rights to the asset and will continue to sell it. China-based Luye said the two parties are discussing the possibility of expanding Xuezhikang to the US and Europe, as well as other emerging markets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.